Debutyldronedarone-d₇ hydrochloride  (Synonyms: SR35021-d₇ hydrochloride)

Debutyldronedarone-d₇ hydrochloride is deuterated labeled Debutyldronedarone hydrochloride (HY-12753A). Debutyldronedarone (SR35021) hydrochloride, the main metabolite of Dronedarone, is a selective thyroid hormone receptor α₁ (TRα₁) inhibitor. Debutyldronedarone hydrochloride inhibits T3 binding to TRα₁ and TRβ₁ by 77% and 25%, respectively. Debutyldronedarone hydrochloride can be used for the research of arrhythmic^[1].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

544.15

C₂₇H₃₀D₇ClN₂O₅S

[2H]C([2H])(C([2H])(CNCCCOC1=CC=C(C=C1)C(C2=C(OC3=C2C=C(C=C3)NS(C)(=O)=O)CCCC)=O)[2H])C([2H])([2H])[2H].Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Van Beeren HC, et al. Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. Endocrinology. 2003 Feb;144(2):552-8.  [Content Brief]